Clinical Trial Update: Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of pembrolizumab and brentuximab vedotin in relapsed/refractory T-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Yale University | Conditions: T-Cell Lymphoma | Phase 2 | Status: RECRUITING